- Home
- PRPL vs SKYE Comparison
PRPL vs SKYE Comparison
Compare PRPL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- SKYE
- Stock Information
- Founded
- PRPL 2010
- SKYE 2012
- Country
- PRPL United States
- SKYE United States
- Employees
- PRPL N/A
- SKYE N/A
- Industry
- PRPL Home Furnishings
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- SKYE Health Care
- Exchange
- PRPL Nasdaq
- SKYE Nasdaq
- Market Cap
- PRPL 90.3M
- SKYE 80.7M
- IPO Year
- PRPL N/A
- SKYE N/A
- Fundamental
- Price
- PRPL $0.66
- SKYE $2.43
- Analyst Decision
- PRPL Buy
- SKYE Buy
- Analyst Count
- PRPL 3
- SKYE 7
- Target Price
- PRPL $1.70
- SKYE $18.67
- AVG Volume (30 Days)
- PRPL 403.9K
- SKYE 136.4K
- Earning Date
- PRPL 03-13-2025
- SKYE 03-21-2025
- Dividend Yield
- PRPL N/A
- SKYE N/A
- EPS Growth
- PRPL N/A
- SKYE N/A
- EPS
- PRPL N/A
- SKYE N/A
- Revenue
- PRPL $504,838,000.00
- SKYE N/A
- Revenue This Year
- PRPL N/A
- SKYE N/A
- Revenue Next Year
- PRPL $1.83
- SKYE N/A
- P/E Ratio
- PRPL N/A
- SKYE N/A
- Revenue Growth
- PRPL N/A
- SKYE N/A
- 52 Week Low
- PRPL $0.65
- SKYE $2.31
- 52 Week High
- PRPL $2.12
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- PRPL 23.09
- SKYE 40.00
- Support Level
- PRPL $0.77
- SKYE $2.40
- Resistance Level
- PRPL $0.85
- SKYE $2.88
- Average True Range (ATR)
- PRPL 0.06
- SKYE 0.24
- MACD
- PRPL -0.02
- SKYE -0.02
- Stochastic Oscillator
- PRPL 4.60
- SKYE 3.74
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.